Clinical trials: Epidermis
Breast Cancer
Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study
This disease registry is a prospective, multicenter non-interventional study designed to observe the different anticancer treatment regimens and their sequencing throughout the course of the disease in participants with…
- Trial name
- ESTHER (NCT02393924)
- Testing
- No intervention
- Where
- 30 sites in United Kingdom
- Volunteers
- 311 people
- Sponsor
- Hoffmann-La Roche
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome
Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
The Boston Keratoprosthesis type I (KPro) is a prosthetic cornea used to treat several causes of corneal blindness. Some categories of patients, including those with auto-immune diseases such as Stevens-Johnson syndrome, toxic…
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome, Mucous Membrane Pemphigoid
- Trial name
- NCT02126020
- Testing
- topical infliximab
- Where
- 2 sites in United States, Canada
- Sponsor
- James Chodosh, MD, MPH
Colorectal Cancer, Colorectal Adenoma
Molecular Imaging of Epidermal Growth Factor Receptor in Colorectal Neoplasia Using Confocal Laser Endomicroscopy
The study aims to: 1. Achieve molecular imaging of EGFR in patients with colorectal neoplasia in vivo using confocal laser endomicroscopy. 2.
- Trial name
- NCT01372189
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong University
Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
Background: It is estimated that in the Netherlands each year approximately 900 patients with gastric cancer or adenocarcinoma of the gastro-oesophageal junction are candidates for chemotherapy.
- Trial name
- B-DOCT (NCT01359397)
- Testing
- Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
- Where
- Netherlands
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
By leveraging a community-based, cancer-specific electronic healthcare record for this study, we aim to understand treatment patterns and clinical outcomes among patients with HR+/HER2- mBC who received care within the context of…
- Trial name
- NCT04460911
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Pfizer
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
The purpose of this study is to determine the safety, the antitumor activity and the pharmacokinetics of ASP8273 in EGFR tyrosine kinase inhibitor (EGFR-TKI)-naïve patients with non-small cell lung cancer (NSCLC) harboring EGFR…
- Trial name
- NCT02500927
- Testing
- ASP8273 Capsules, ASP8273 Capsules A
- Where
- 11 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Astellas Pharma Inc
Neoplasms, Therapy-Associated
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation
This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal growth factor receptor gene…
- Trial name
- NCT02283424
- Testing
- Icotinib, chemotherapy (Carboplatin and Docetaxel)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Breast Neoplasm
Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer
The primary objective of this study is to determine whether overall response to cetuximab combined with cisplatin is better than overall response to cisplatin alone together with showing that the overall response for cetuximab…
- Trial name
- BALI-1 (NCT00463788)
- Testing
- cetuximab, cisplatin, cisplatin
- Where
- 46 sites in Australia, Austria and 9 more
- Volunteers
- 181 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Carcinoma, Non-Small-Cell Lung
GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations
This observational study will investigate the efficacy, safety, tolerability and symptom control of GIOTRIF (Afatinib) in daily routine first-line therapy in patients with locally advanced or metastatic NSCLC harboring…
- Trial name
- NCT02047903
- Testing
- Afatinib
- Where
- Germany
- Volunteers
- 161 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer
An observational study in patients with advanced ER+, HER2 negative breast cancer, who are treated with everolimus and exemestane in combination.
- Trial name
- NCT02023359
- Testing
- Everolimus and exemestane
- Where
- 3 sites in Denmark
- Volunteers
- 7 people
- Sponsor
- Novartis Healthcare A/S
EGFR Inhibitor-associated Rash
Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
This is a clinical research study of an experimental new medication, Menadione Topical Lotion (MTL). The study lotion is experimental and has not been approved for public use.
- Trial name
- NCT00656786
- Testing
- Menadione Topical Lotion
- Where
- 7 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Lung Cancer
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
This is an open-label, single-arm, multicenter, exploratory Phase II study sponsored by Astrazeneca Investment (China) Co., LTD.
- Trial name
- MINOVA (NCT05215951)
- Testing
- osimertinib
- Where
- 6 sites in China
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Pachyonychia Congenita
Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Pachyonychia Congenita (pEDD-PC)
The goal of this clinical trial is to learn if KM-023 is safe and well tolerated in adults with Pachyonychia Congenita (PC). The study will also explore whether KM-023 may help reduce pain, improve mobility, and lessen the impact…
- Trial name
- NCT07893483
- Testing
- KM-023
- Where
- 2 sites in Israel
- Volunteers
- 10 people
- Sponsor
- Orvida Pharma (formerly Kamari Pharma)
Non Small Cell Lung Cancer
XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
The trial is divided into two parts, one is dose escalation phase, the second one is dose expansion phase. For dose escalation phase, the main purpose is to evaluate safety and tolerability of XZP-5809-TT1 tablets after treatment…
- Trial name
- NCT04622072
- Testing
- XZP-5809-TT1 Tablet
- Where
- 5 sites in China
- Volunteers
- 21 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Epidermal Nevi, Nevus Sebaceus
12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi
This study of NFX-179 is an open-label study, evaluating safety, tolerability, pharmacodynamic activity, and the clinical effect in subjects with Epidermal Nevus(ENS). NFX-179 is formulated as a gel for topical administration.
- Trial name
- NCT05195762
- Testing
- NFX-179 Gel 1.50%
- Where
- United States
- Sponsor
- Albert Chiou
HER2 Status in Breast Cancer
Updates and Insights on HER2 in Breast Cancer in Sohag Governorate
To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors. To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67…
- Trial name
- HER2 (NCT07758127)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Squamous Cell Tumors
A Study of ABT-414 in Subjects With Solid Tumors
A study of ABT-414 in subjects with solid tumors.
- Trial name
- NCT01741727
- Testing
- ABT-414
- Where
- 6 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Glioblastoma
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly…
- Trial name
- NCT05187624
- Testing
- RO7428731
- Where
- 8 sites in United States, Australia and 3 more
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)
According to the recent report using EGFR tyrosine kinase inhibitors (EGFR-TKI), there is all over survival of the EGFR gene mutation-positive NSCLC in a tendency to extension.
- Trial name
- NCT02475720
- Where
- Japan
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
EGFR Gene Mutation, Nonsmall Cell Lung Cancer
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
This is a study for patients with advanced non-small cell lung cancer with changes to their cancer cells called EGFR mutations. Mutated EGFR is important in the growth of cancer cells.
- Trial name
- NCT02954523
- Testing
- Dasatinib, Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Chul Kim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.